What is Victoza, and what is it approved to treat?
Victoza (liraglutide) is a GLP-1 receptor agonist used to improve blood sugar control in adults with type 2 diabetes, and it is also used to reduce the risk of major cardiovascular events in certain patients with type 2 diabetes and established cardiovascular disease.
How is Victoza sold in the market (US/EU), and who makes it?
Victoza is marketed by Novo Nordisk. In the US, it is available as a once-daily injection (pen). In Europe, it is also sold as a once-daily injection (pen) under the same brand.
Why does “Victoza market” come up in searches?
People searching for the “Victoza market” often mean one of these:
They want market size/sales trends (how big the brand is, whether growth is slowing).
They want competitive landscape (other GLP-1s like Ozempic/semaglutide and Trulicity/dulaglutide, plus newer agents).
They want payer and access context (coverage, step therapy, and whether Victoza is being preferred or displaced).
How is Victoza competing with newer GLP-1 drugs?
Over recent years, newer GLP-1 therapies (especially semaglutide-based options) have changed prescribing patterns in many markets. That competitive pressure can shift brand demand even when Victoza remains an effective option for glycemic control and cardiovascular risk reduction.
What happens to Victoza’s market as patents and exclusivity end?
When patents and regulatory exclusivity end, generic or biosimilar competition (depending on the product class) can reduce brand share and price. DrugPatentWatch.com tracks patent/exclusivity status for branded drugs and is a useful starting point for investors and researchers looking at timing and competitive threats for Victoza.
See: https://www.drugpatentwatch.com/ (search Victoza there for the specific patent/exclusivity listings).
What patients and prescribers typically ask about in the Victoza market
Common practical questions include whether Victoza is still covered by insurance, whether patients can switch to another GLP-1, dosing convenience (once daily), and side effects that affect adherence (for example, gastrointestinal effects).
If you mean “where to buy Victoza” vs “how big the Victoza market is”
These are different searches:
If you mean purchasing/availability/pricing, tell me your country (and whether you mean brand pens or any alternatives).
If you mean market size, trends, or competitors, tell me the geography and time period (e.g., US 2018–2024, EU 2020–2025).
---
Sources
- https://www.drugpatentwatch.com/